BTIG Upgrades United Therapeutics Corp. (UTHR) to Buy

BTIG upgraded United Therapeutics Corp. (NASDAQ: UTHR) from Neutral to Buy with a price target of $225.00.

Analyst Hartaj Singh said, "United Therapeutics to Buy from Neutral, based on our belief that UTHR is on the verge of 4-9% above-consensus revenue growth in 2016/17E. Its unique operating model will leverage this into extremely strong non GAAP EPS growth—we believe 14-25% above consensus. The revenue growth is due to the company’s unique product mix in PAH, while non-GAAP EPS growth comes from exceptional cost discipline and share buybacks. As the Street comes to appreciate this, we believe UTHR will outperform its peer group."

For an analyst ratings summary and ratings history on United Therapeutics Corp. click here. For more ratings news on United Therapeutics Corp. click here.

Shares of United Therapeutics Corp. closed at $172.75 yesterday.

You May Also Be Interested In

• Wells Fargo Upgrades Neurocrine Bio. (NBIX) to Overweight 'as the Company is Knocking on the Doors of the Large-Cap Club'
• 'Catalysts on the horizon:' Airbnb (ABNB) upgraded to Buy at Mizuho, shares climb
• Deutsche Bank Upgrades MSCI Inc. (MSCI) to Buy, 'Compelling entry point for long-term investors'